Article

Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor Responders

2021-12-02

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Objective</h4> To determine if poor responders to COVID-19 RNA vaccines (<50% neutralisation) after two doses would remain poor responders, or if a third dose could elicit high levels of NAbs. <h4>Design</h4> Clinical follow-up study <h4>Setting</h4> Academic and medical institutions in USA <h4>Participants</h4> 269 healthy individuals ranging in age from 19 to 80 (Average age = 51; 165 femal...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0e9ffb1b-170a-5e11-b24d-a526a8181e33
DOI: 10.1101/2021.11.30.21266716

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Third COVID-19 Vaccine Dose Boosts Neutralising Antibodies in Poor RespondersDOI 10.1101/2021.11.30.21266716Read

Third COVID-19 Vaccine Dose Boosts Neutralizing Antibodies in Poor RespondersSemantic proximity Read

Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-upSemantic proximity Read

Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity Read

SARS-CoV-2 Omicron Variant Infection of Individuals with High Titer Neutralizing Antibodies Post-3<sup>rd</sup> mRNA Vaccine DoseSemantic proximity Read

Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trialSemantic proximity Read

Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccineSemantic proximity Read

Immunogenicity and clinical outcomes of booster mRNA vaccine BNT162b2 in primary antibody deficienciesSemantic proximity Read

Immune Response and Reactogenicity After Immunization With a Suboptimal Two-Dose mRNA Vaccine Followed by a Full Vaccination With a Standard mRNA Vaccine Compared to a Prime-Boost Regimen of a Standard mRNA Vaccine: A Multicenter Cohort StudySemantic proximity Read

Increased seroprevalence and improved antibody responses following third primary SARS-CoV-2 immunisation: an update from the COV-AD studySemantic proximity Read

Neutralising antibodies predict protection from severe COVID-19Semantic proximity Read

Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and - experienced subjectsSemantic proximity Read

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trialSemantic proximity Read